Key View

• Merck has bolstered its oncology pipeline with its latest licencing agreement with Orion.
• The two companies will co-develop and co-commercialise an experimental prostate cancer drug.
• The deal will significantly benefit Orion, as it makes another successful deal with a major pharma player. The company has raised its full-year outlook

Key View

• At Fitch Solutions, we have lowered our German real GDP growth forecast for 2022 from 2.0% to 1.7%, following downward revisions to our global growth projections.
• German output and exports of manufactured goods will face significant limitations over H222 due to supply-side headwinds and constraints on external demand.
• We expect pent

Key View

• Russia's invasion of Ukraine will significantly weaken our outlook for German vehicle production in 2022 as automakers are already dealing with a shortage of semiconductors, batteries and other components.
• Over the long term (2023-2031) we also expect vehicle production growth to remain relatively flat as German automakers have

Key View

• Germany's consumer spending growth will be positive in 2022, as spending returns to more conventional trends. We forecast real household spending to grow by 1.4% in 2022, accelerating from the estimated 0.15% growth in 2021. The lifting of Covid-19 related restrictions amid and improving epidemiological situation will aid consumer

Key View

• BioNTech presented preliminary data on the use of mRNA vaccine technology in combination with CAR-T cell therapy at the 2022 AACR Annual Meeting.
• With compelling early results, the study represents a significant step forward for BioNTech's burgeoning mRNA oncology pipeline.
• Industry competition is set to increase as mRNA technology

Key View

• At Fitch Solutions we now forecast German real GDP growth at 2.0% in 2022, down from 3.1%.
• Our latest revision comes on the back of intensified downward pressures on Germany’s manufacturing sector from the fallout of the Russian invasion of Ukraine.
• While we do expect domestic demand to strengthen as pandemic-related restrictions

Key View

• The collaboration between BioNTech and Medigene will accelerate the rate of immunology research with TCR therapy.
• The agreement will increase BioNTech’s already strong and innovative oncology pipeline, featuring collaborations with numerous major pharmaceutical companies.
• It will also continue Medigene’s development strategy of